Home > Pulmonology > NLC 2022 > Interstitial Lung Diseases (ILD) > Update on treatment of fibrotic ILD

Update on treatment of fibrotic ILD

Presented By
Dr Elisabeth Bendstrup, Aarhus University Hospital, Denmark
Conference
NLC 2022
Doi
https://doi.org/10.55788/ac4dcf53
The definition of progressive fibrotic-interstitial lung disease (PF-ILD) has been replaced by the more adequate definition of progressive pulmonary fibrosis (PPF). Antifibrotic therapy has shown to benefit patients with idiopathic pulmonary fibrosis (IPF)/PPF; and with an increasing number of new treatment modalities currently in the pipeline, outcomes for patients will – hopefully – continue to improve in the future. The ATS/ERS/JRS/ALAT Clinical Practice Guidelines have proposed a new definition of PPF which requires at least two of three criteria within the past year without an alternative explanation in a patient with an ILD other than IPF (see Table) [1]. Table: New definition of PPF according to ATS/ERS/JRS/ALAT Clinical Practice Guidelines [1] In a patient with ILD of known or unknown aetiology other than IPF who has radiological evidence of pulmonary fibrosis, PPF is defined as ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on